EA201300436A1 - Совместные кристаллы и соли ингибиторов ccr3 - Google Patents

Совместные кристаллы и соли ингибиторов ccr3

Info

Publication number
EA201300436A1
EA201300436A1 EA201300436A EA201300436A EA201300436A1 EA 201300436 A1 EA201300436 A1 EA 201300436A1 EA 201300436 A EA201300436 A EA 201300436A EA 201300436 A EA201300436 A EA 201300436A EA 201300436 A1 EA201300436 A1 EA 201300436A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
ccr3 inhibitors
crystals
ccr3
joint crystals
Prior art date
Application number
EA201300436A
Other languages
English (en)
Other versions
EA201300436A8 (ru
EA029097B1 (ru
Inventor
Маркус Франк
Ханс Хеберле
Манюэль Анри
Томас Пахур
Марко Сантагостино
Уве Штертц
Томас Требинг
Ульрике Вертманн
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201300436A1 publication Critical patent/EA201300436A1/ru
Publication of EA201300436A8 publication Critical patent/EA201300436A8/ru
Publication of EA029097B1 publication Critical patent/EA029097B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

В заявке описаны совместные кристаллы и соли ингибиторов CCR3 формулы (1)содержащие их фармацевтические композиции и способы их применения в качестве средств, предназначенных для лечения и/или предупреждения заболеваний, связанных с рецептором CCR3.
EA201300436A 2010-10-07 2011-10-06 Совместные кристаллы и соли ингибиторов ccr3 EA029097B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186901 2010-10-07
PCT/EP2011/067437 WO2012045803A1 (en) 2010-10-07 2011-10-06 Co-crystals and salts of ccr3-inhibitors

Publications (3)

Publication Number Publication Date
EA201300436A1 true EA201300436A1 (ru) 2013-08-30
EA201300436A8 EA201300436A8 (ru) 2018-01-31
EA029097B1 EA029097B1 (ru) 2018-02-28

Family

ID=44741339

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300436A EA029097B1 (ru) 2010-10-07 2011-10-06 Совместные кристаллы и соли ингибиторов ccr3

Country Status (36)

Country Link
US (3) US8742115B2 (ru)
EP (1) EP2625174B1 (ru)
JP (1) JP5794713B2 (ru)
KR (3) KR101844215B1 (ru)
CN (1) CN103140486B (ru)
AP (1) AP3268A (ru)
AR (1) AR083353A1 (ru)
AU (1) AU2011311530B2 (ru)
BR (2) BR122021010665B1 (ru)
CA (1) CA2807255C (ru)
CL (1) CL2013000488A1 (ru)
CO (1) CO6710910A2 (ru)
CY (1) CY1116168T1 (ru)
DK (1) DK2625174T3 (ru)
EA (1) EA029097B1 (ru)
EC (1) ECSP13012600A (ru)
ES (1) ES2535264T3 (ru)
GE (1) GEP20166488B (ru)
HR (1) HRP20150419T1 (ru)
HU (1) HUE024540T2 (ru)
IL (1) IL224269A (ru)
MA (1) MA34545B1 (ru)
ME (1) ME02040B (ru)
MX (1) MX2013003785A (ru)
MY (1) MY167898A (ru)
NZ (1) NZ605827A (ru)
PE (1) PE20140188A1 (ru)
PL (1) PL2625174T3 (ru)
PT (1) PT2625174E (ru)
RS (1) RS53858B1 (ru)
SG (1) SG188949A1 (ru)
SI (1) SI2625174T1 (ru)
TW (1) TWI546294B (ru)
UA (1) UA109290C2 (ru)
UY (1) UY33655A (ru)
WO (1) WO2012045803A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) * 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
AU2018248425B2 (en) 2017-04-05 2024-03-28 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
JP2020536929A (ja) * 2017-10-13 2020-12-17 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
BR112021004938A2 (pt) * 2018-09-26 2021-06-01 Alkahest, Inc. métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
AU2021287906A1 (en) * 2020-06-11 2022-12-15 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6936718B2 (en) 2001-11-29 2005-08-30 Schering Corporation Preparation of rotamer mixtures of pharmaceutical salts
EP1596869B1 (en) * 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
KR20060061393A (ko) 2003-10-24 2006-06-07 에프. 호프만-라 로슈 아게 Ｃｃｒ3 수용체 길항제
US7705153B2 (en) 2004-02-05 2010-04-27 Schering Corporation Bipiperdine derivatives useful as CCR3 antagonists
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
JP2006137718A (ja) 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2007116313A2 (en) 2006-04-12 2007-10-18 Pfizer Limited Pyrrolidine derivatives as modulators of chemokine ccr5 receptors
DE602007008222D1 (de) 2006-04-20 2010-09-16 Hoffmann La Roche Diazepanderivate als modulatoren von chemokinrezeptoren
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
DK2625174T3 (da) 2015-02-02
CA2807255A1 (en) 2012-04-12
PE20140188A1 (es) 2014-02-26
CN103140486B (zh) 2016-08-03
KR20130118313A (ko) 2013-10-29
US20120264729A1 (en) 2012-10-18
EA201300436A8 (ru) 2018-01-31
SG188949A1 (en) 2013-05-31
ES2535264T3 (es) 2015-05-07
CN103140486A (zh) 2013-06-05
EA029097B1 (ru) 2018-02-28
AU2011311530A1 (en) 2013-01-31
EP2625174A1 (en) 2013-08-14
BR112013008211A2 (pt) 2016-06-21
AR083353A1 (es) 2013-02-21
JP2013542207A (ja) 2013-11-21
CL2013000488A1 (es) 2013-07-05
ME02040B (me) 2015-05-20
BR122021010665B1 (pt) 2022-03-15
ECSP13012600A (es) 2013-07-31
KR102163874B1 (ko) 2020-10-12
KR20180005717A (ko) 2018-01-16
AP2013006679A0 (en) 2013-01-31
KR20190104645A (ko) 2019-09-10
GEP20166488B (en) 2016-06-10
US20140135307A1 (en) 2014-05-15
US9233950B2 (en) 2016-01-12
WO2012045803A1 (en) 2012-04-12
RS53858B1 (en) 2015-08-31
AU2011311530B2 (en) 2015-04-09
TWI546294B (zh) 2016-08-21
KR101844215B1 (ko) 2018-04-03
KR102239690B1 (ko) 2021-04-13
JP5794713B2 (ja) 2015-10-14
CY1116168T1 (el) 2017-02-08
PL2625174T3 (pl) 2015-06-30
UA109290C2 (uk) 2015-08-10
MA34545B1 (fr) 2013-09-02
CA2807255C (en) 2018-11-13
SI2625174T1 (sl) 2015-03-31
NZ605827A (en) 2015-09-25
BR112013008211B1 (pt) 2021-08-24
UY33655A (es) 2012-04-30
HUE024540T2 (hu) 2016-01-28
US8742115B2 (en) 2014-06-03
HRP20150419T1 (hr) 2015-05-22
MX2013003785A (es) 2013-06-05
US20150105371A1 (en) 2015-04-16
CO6710910A2 (es) 2013-07-15
PT2625174E (pt) 2015-03-09
MY167898A (en) 2018-09-26
IL224269A (en) 2017-08-31
BR112013008211A8 (pt) 2017-10-10
AP3268A (en) 2015-05-31
TW201305134A (zh) 2013-02-01
EP2625174B1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MD20150043A2 (ru) Ингибиторы гистон деметилаз
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
ATE530524T1 (de) Substituierte sulfonamid-derivate
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201390683A1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
EA201590562A1 (ru) Бензамиды
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos